Cyclooxygenase Inhibitors

Life Span and Spontaneous Tumors Incidence of the Wistar Mishima (WM/MsNrs) Rat.

“…Particularly the life span in females was prolonged after the age of the 50 percentile of the survival rate (Table 3). A distinct sex difference in the life span was also observed in other strains [9,15,20].…”

“…That of WM/MsNrs female rats was 20.1% of all observed rats and occupied 74.2% of rats with tumors. The value was higher than those in Wistar of less than 2 years old [1,2] and Brown Norway rats [9] and Fischer 344 rats [17], similar to that in Wistar rats [18], and lower than those in Sprague-Dawley rats [5,12], and Donryu rats [11]. Although the times of mammary tumor onset and development of mammary tumor in size were not recorded in this study, the tumors tended to appear at over 18-24 months of age.…”

“…In females, the mammary tumor in WM/MsNrs rats was often observed, and the incidence and the symptoms were as described above. The incidences of tumors in the ovary, uterus, lung, liver, and bones being in the range 0.9-3.4% were lower than those of other strains including Wistar rats [1,2,9,11]. Although previous studies have shown that other tumors, e.g., in pituitary and adrenal glands and leukemia, were frequently observed in rats [11,12,16], we could not compare our results because the organs observed were limited in this study.…”

Anti-inflammation induced by counter-irritation or by treatment with non-steroidal agents inhibits the growth of a tumour of non-detected immunogenicity

“…The molecular basis of concomitant resistance remains unknown, but it is speculated that several mechanisms may be acting either simultaneously or sequentially. It has been demonstrated in our laboratory that, although non-immunogenic, the LB tumour can induce concomitant resistance (Ruggiero et al, 1985), and that inhibition of secondary LB tumour growth by the presence of a primary tumour is abrogated if inflammatory M4s are injected into the secondary site of tumour cell implantation (Bustuoabad et al, 1984 Administration of different NSAIAs as a single agent to inhibit tumour growth has been attempted (Humes et al, 1974;Lynch et al, 1978;Bennet et al, 1979Bennet et al, , 1982Bennet et al, , 1985Narisawa et al, 1981;Panje, 1981;Pollard & Luckert, 1981;McCormick & Moon, 1983;Caignard et al, 1984;Fulton, 1984;Rubio, 1984;McCormick et al, 1985;Kort et al, 1986). Piroxicam treatment inhibits colon carcinogenesis (Pollard & Luckert, 1983;Reddy et al, 1987) in rats, and in combination with an anti-neoplastic agent it has also been used in man (Braun et al, 1987).…”